E.E. Geduld’s Agios Pharmaceuticals AGIO Stock Holding History

E.E. Geduld’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-15,000	Closed	-$792K	–	180
2016 Q3	$792K	Buy	+15,000	New	+$653K	0.79%	20
2015 Q2	–	Sell	-2,500	Closed	-$236K	–	293
2015 Q1	$236K	Buy	+2,500	New	+$280K	0.16%	146
2013 Q4	–	Sell	-16,000	Closed	-$447K	–	318
2013 Q3	$447K	Buy	+16,000	New	+$442K	0.27%	101

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

E.E. Geduld's AGIO Position: Q4 2016 in Review

E.E. Geduld sold out of Agios Pharmaceuticals (AGIO) in Q4 2016, closing a stake of 15,000 shares — an estimated $792K sold.

E.E. Geduld first reported a position in AGIO in Q3 2013 and held it in 3 quarters. The position peaked at $792K in Q3 2016. 161 funds tracked by Wall St. Rank hold AGIO as of Q4 2016.

E.E. Geduld reported no remaining Agios Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
E.E. Geduld sold 15,000 Agios Pharmaceuticals shares in Q4 2016, an estimated $792K.
E.E. Geduld first reported a position in Agios Pharmaceuticals in Q3 2013 and held it in 3 quarters.
E.E. Geduld's Agios Pharmaceuticals position peaked at $792K in Q3 2016.
161 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2016.

Based on E.E. Geduld's 13F filing for Q4 2016, filed 8 Feb 2017.